



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/689,122	10/20/2003	Tabassum Naqvi	3817.14-1	4234
7590 Hana Verny Peters, Verny, Jones & Schmitt LLP Suite 230 425 Sherman Avenue Palo Alto, CA 94306		12/13/2007	EXAMINER HAQ, SHAFIQUA	
			ART UNIT 1641	PAPER NUMBER
			MAIL DATE 12/13/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/689,122	NAQVI ET AL.	
	Examiner	Art Unit	
	Shafiqul Haq	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 29 October 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-4 and 6-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-4 and 6-8 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some *
 - c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____.

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/29/07 has been entered.
2. Claims 1-4 and 6-8 are pending and under active prosecution.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-4 and 6-8 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Sportsman et al. (US 6,806,053 B1) in view of Iwasaki et al. (J. Biol. Chem. 2002) and Hirata et al. (J. Biol. Chem. 1990).

Sportsman et al. in a cell-signaling assay of inositos-phospholipid signaling pathway, disclose detection of intermediate 1, 4, 5 IP₃ of the singnaling pathway. The assay include a tracer from the intermediate (i.e. tracer of 1,4, 5 IP₃) and a specific binding partner for 1,4,5 IP₃ (intermediate) and the tracer (e.g. labeled 1,4, 5 IP₃). Sportsman et al. also disclose that the tracer may include a luminophore attached by a suitable chemistry to the intermediate (e.g. a fluorescein succinyl-

Art Unit: 1641

labeled IP₃) (column 20, example 14 and figs. 5, 6, 7A, 7B, 8A and 8B). Sportsman et al. disclose that specific binding partner generally comprises any compound capable of specifically and competitively binding an analyte and an associated tracer and also disclose that fragments, derivatives or analogs of a preferred specific binding partner may be used (column 11, lines 22-35).

Sportsman et al., however, do not disclose IP₃R receptor or fragments thereof as specific binding partner in this assay.

Iwasaki et al. disclose IP₃R antagonists that strongly and specifically bind to IP₃ (analyte). Iwasaki et al. also disclose N-terminal ligand binding domain of mIP₃R1 comprising amino acid sequence 226-578 as the core region for high affinity binding to IP₃ and the binding affinity is approximately 1000 times greater than that of endogenous IP₃T (see page 2764, left column, lines 6-21).

Since a specific and a strong binding partner for IP₃ is disclosed by Iwasaki et al., it would have been obvious at the time of the invention to a person of ordinary skill in the art to include core region of the IP₃R as taught by Iwasaki et al in the assay method of Sportsman to effectively measure IP₃ in a sample with a reasonable expectation of success because specific binding partner for IP₃ is envisaged in the method of Sportsman et al.

As for conjugate of IP₃ with a detectable label, Sportsman et al. disclose that the tracer may include a luminophore attached by a suitable chemistry to the intermediate (e.g. a fluorescein succinyl-labeled IP₃)(column 20, example 14) but, however, fail to disclose detectable label at the 2-hydroxy position of IP₃.

Hirata et al. disclose a series of 1,4,5-triphosphate (IP₃) analogs with substituents at 2 hydroxy position and disclose that such modification (substitution at 2-hydroxy position) do not substantially interfere with the affinity of IP₃ for IP₃ receptor (see abstract and page 8404, right column, lines 6-13).

Therefore, given the above fact that 2-hydroxyl position of IP3 can be substituted with organic groups without significantly affecting binding affinity of IP₃ for its binding partner (Hirata et al.), it would have been obvious at the time of the invention to a person of ordinary skill in the art to attach luminophore at the 2-hydroxy position of IP₃ in the IP₃-luminophore conjugate as suggested by Sportsman et al with a reasonable expectation of success because attachment by a suitable chemistry is disclosed by Sportsman et al. and substitution at the 2 hydroxyl position known for IP3, which does not affect IP3 binding affinity to its binding partner.

As for dependent claim 2, Sportsman et al. disclose that the assay may be homogeneous (column 9, lines 49-52). As for claims 4 and 6 Iwasaki disclose amino acid sequence 226-578 as the core region for high affinity binding to IP₃ and disclose a amino acids 224-604 of mouse IP3R fused to glutathione S-transferase to efficiently express the core region as a soluble active form (IP3 sponge) (page 2764, left column, lines 6-18) and as for claims 18-19, Sportsman et al. disclose component in a kit format (column 13, lines 34-35) and the packaging of components in kit form is a well-known obvious expedient for ease and convenience in assay performance and once a method has been established, one skilled in the

Art Unit: 1641

art would clearly consider compiling in a kit format and change/modify different components of the kit to best suit the assay.

Response to Argument

5. Applicant's arguments filed 10/29/07 have fully been considered, and are persuasive to overcome the rejection under 35 USC 112, first paragraph but the argument is not persuasive to overcome the rejections under 35 USC 103 as set forth in this office action of 6/19/07.

With regard to 35 USC 103 rejections over sportsman et al., Applicants argued that Hirata does not teach that 2-derivatives can successfully compete for IP₃ receptor. Applicants further argued that "sponge" protein is not the IP₃ receptor, rather it is a fragment of the receptor that has 1000 fold greater affinity for IP₃ than the intact receptor and Iwasaki does not determine the specificity of this sponge protein. These arguments are not persuasive because Hirata et al. clearly disclose that substitution at the 2-hydroxy group of inositol 1,4,5 triphosphate (IP₃) with bulky organic groups did not reduce the ability of the analog to interact with receptor sites.

See page 8404 of right column which states that following:

"It is important, therefore, to understand what structural features of D-IP₃ are essential for activity, any by chemical modification of the molecule to build up structure-activity profiles for the interaction of D-IP₃ with receptor sites and with the metabolic enzymes 5-phosphatase and 3-kinase .

Most recently, we synthesized a series of IP₃ analogs in which the bulky substituent such as 4-azidobenzoyl (designated as analog 195), 4-(benzamidoethyl-2-hydroxyphenylazo)benzoyl (204), ----- are coupled with

Art Unit: 1641

the 2-hydroxyl group of IP₃. Using these analogs, we found that such modifications reduced little the ability of the analogs to interact with receptor sites"

Since, sponge protein comprises potential binding portion of the inositol 1,4,5-triphosphate receptor (IP₃ receptor) (i.e. derived from 1,4,5-IP₃R binding domain) and strongly and specifically competed with endogenous 1,4,5-IP₃R for binding to IP₃ (Iwasaki et al. page 2763, left column, lines 13-17 and page 2764, lines 6-21), it would be expected to have similar binding profile towards IP₃ and 2 hydroxy substituted IP₃ analogs (substitution at 2 hydroxyl position) as that of native IP₃R. Furthermore, if one is to prepare an IP₃ tracer (i.e. IP₃ conjugated to a label) as suggested by Sportsman et al, there would be options for linking the label at one of the three possible substitution positions (2, 3 and 6 hydroxyl positions) of inositol 1,4,5-triphosphate (a ligand for 1,4,5-IP₃R) and with the motivating disclosure in hand (i.e. substitution at 2 hydroxyl position does not reduce binding ability of the analog to interact with the receptor, Hirata et al), one of ordinary skill in the art would obviously first try the 2-hydroxyl position to link the label.

Applicants argued that Iwasaki does not determine the specificity of this sponge protein and while it has a 1000 fold higher affinity for IP₃ than the natural receptor, it is not tested for its specificity to other phosphate derivatives of inositol. Applicant's argument that Iwasaki does not teach a specificity to other phosphate derivatives is irrelevant, as such is not required in the claims and the features upon which applicant relies (i.e. reactivity to other phosphate derivative) are not recited in the rejected claim(s). Iwasaki is concerned with the characterization of inositol 1,4,5-

triphosphate receptor and sponge protein (potential binding domain) derived from the inositol 1,4,5-triphosphate receptor and discloses that 1,4,5-triphosphate receptor (IP₃) is responsive to inositol 1,4,5-triphosphate (IP₃) (i.e. specific for inositol 1,4,5-triphosphate). Moreover, since the sponge protein of Iwasaki comprises the same amino acid sequence as that of Applicants' sponge protein, binding specificity to other phosphate derivatives of inositol would be similar as well (i.e. inherently present in the sponge protein of Iwasaki).

Applicants are reminded that prior art is not limited just to the references being applied, but includes the understanding of one of ordinary skill in the art. The prior art reference (or references when combined) need not teach or suggest all the claim limitations. The "mere existence of differences between the prior art and an invention does not establish the invention's nonobviousness." The gap between the prior art and the claimed invention may not be "so great as to render the [claim] nonobvious to one reasonably skilled in the art." In determining obviousness, neither the particular motivation to make the claimed invention nor the problem the inventor is solving controls. The proper analysis is whether the claimed invention would have been obvious to one of ordinary skill in the art after consideration of all the facts. Factors other than the disclosures of the cited prior art may provide a basis for concluding that it would have been obvious to one of ordinary skill in the art to bridge the gap. The teaching, suggestion, or motivation test is flexible and an explicit suggestion to combine the prior art is not necessary. The motivation to combine may be implicit and may be found in the knowledge of one of ordinary skill in the art, or, in

some cases, from the nature of the problem to be solved. “[A]n implicit motivation to combine exists not only when a suggestion may be gleaned from the prior art as a whole, but when the ‘improvement’ is technology-independent and the combination of references results in a product or process that is more desirable, for example because it is stronger, cheaper, cleaner, faster, lighter, smaller, more durable, or more efficient. Furthermore, one cannot show nonobviousness by attacking references individually wherein the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merk & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fines*, 837 F.2d 1071, 5USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case Sportsman et al. disclose an assay for detection of IP₃ which includes a tracer (tracer i.e. a labeled IP₃) and a specific binding partner for IP₃ and the tracer. Sportsman et al. also disclose that the tracer may include a luminophore attached IP₃ (e.g. a fluorescein succinyl-labeled IP₃). Sportsman et al. disclose that specific binding partner generally comprises any compound capable of specifically and competitively binding an analyte and an associated tracer and also disclose that fragments, derivatives or analogs of a preferred specific binding partner may be used (column 11, lines 22-35). Therefore, Sportsman et al. disclose strong

motivation to include IP₃ binding partners or fragments thereof in the assay methods. Iwasaki's reference is combined with Sportsman et al. because Iwasaki et al. disclose a potential binding partner for IP₃ (i.e. IP₃ receptor or fragment of IP₃R) and disclose that N-terminal 226-578 amino acid sequence of mIP3R1 binds IP₃ with high affinity and thus would be obvious to try as a binding partner in the method as taught by Sportsman et al. for detection of IP3. Hirata's reference is combined with Sportsman because Sportsman et al. envisioned IP₃ tracer in the competitive immunoassay method (i.e. IP₃ labeled with a detectable molecule) and Hirata et al. disclose 2 hydroxyl position of IP₃ as a potential position for substitution with an organic group that do not substantially affect the affinity of IP₃ for IP₃ receptor and thus one of ordinary skill in the art would obviously try to link detectable molecules at that position (i.e. 2-hydroxyl position) as this position is a potential position for substitution that does not significantly interfere with binding to it's binding partner. Therefore, strong motivation is there to combine the references.

Conclusion

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and

Art Unit: 1641

any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

7. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Yoshikawa et al. (Biochem. Biophy. Res. Comm. 1999) disclose important region of binding domain of IP3 receptor for binding to IP3.


Riley et al. (J. Biol. Chem. 2002) disclose PEG linker at 2-hydroxyl position of IP3 more potent than IP3.

Morris et al. (Biochem. J. 2002) disclose that IP3 binding site lies within the N-terminal between residues 226 and 576 and the first 225 residues may inhibit IP3 binding.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shafiqul Haq whose telephone number is 571-272-6103. The examiner can normally be reached on 7:30AM-4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


SHAFIQUL HAQ
EXAMINER
ART UNIT 1641

 "107/07
LONG V. LE
SUPERVISORY PATENT EXAMINER
ART UNIT 1641